Rani Therapeutics Holdings, Inc.
NASDAQ:RANIBiotechnology
-$0.04 today
- Market cap
- $52.19M
- Beta
- 0.76
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.16
Volume 0.23M
Average 1.15M
RANI Total Liabilities
Everything the company owes to creditors and other parties.
Rani Therapeutics Holdings, Inc.NASDAQ: RANI
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 44.6% from a year ago
Total liabilities stood at $16.34M at the end of Q1 FY2026, down 44.6% from a year earlier and down 4.5% from the prior quarter. Over 3 fiscal years it compounded at -20.5% a year.
Context
- Total liabilities amounted to 31.5% of total assets at the end of Q1 FY2026, down 90.7 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -44.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 17.11M USD
- Year-over-year change
- -48.4%
- 4-year CAGR
- +59.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.11M | -48.4% |
| FY2024 | 2024-12-31 | 33.14M | +2.1% |
| FY2023 | 2023-12-31 | 32.47M | -4.6% |
| FY2022 | 2022-12-31 | 34.02M | +1188.8% |
| FY2021 | 2021-12-31 | 2.64M | — |
Total Liabilities vs competitors
How RANI compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -44.6% is the lowest of 9, against a peer median of +33.4%.
- Total liabilities amounts to 31.5% of total assets for RANI, versus a peer median of 55.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $157.69M USD | +131.9% | +106.7% | 81.4% | |
| Dec 2025 | €84.39M EUR | -17.4% | -18.1% | 134.6% | |
| Mar 2026 | $78.92M USD | -2.9% | -34.8% | 131.6% | |
| Mar 2026 | $30.78M USD | +146.7% | +20.0% | 11.9% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $24.13M USD | +25.4% | +20.8% | 106.3% |
| Mar 2026 | CHF 19.15M CHF | +48.4% | -7.0% | 21.9% | |
| Mar 2026 | $18.14M USD | +41.4% | -14.7% | 12.6% | |
| Mar 2026 | $16.34M USD | -44.6% | -20.5% | 31.5% | |
| Mar 2026 | $14.46M USD | +3.8% | +18.8% | 29.4% | |
| Peer median (excluding RANI) | — | +33.4% | +5.9% | 55.4% | |
Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 117.45M | 27.01M | 5.86M | 3.76M | 18.62M |
| Short-term Investments | 0 | 71.48M | 42.68M | 23.88M | 31.09M |
| Net Receivables | 0 | 0 | 200K | 428K | 2.04M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 500K | 800K | 1.68M | 1.57M |
| Total Current Assets | 119.6M | 100.92M | 50.85M | 29.74M | 53.32M |
| Property, Plant & Equipment (Net) | 4.61M | 7.1M | 6.82M | 6.64M | 5.05M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 246K | 246K | 246K |
| Total Non-current Assets | 4.61M | 7.1M | 7.07M | 6.89M | 5.3M |
| Total Assets | 124.21M | 108.03M | 57.92M | 36.63M | 58.62M |
| Account Payables | 1.08M | 1.46M | 648K | 1.36M | 309K |
| Short-term Debt | 0 | 0 | 4.9M | 15M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 1.21M | 0 | 6.83M |
| Other Current Liabilities | 398K | 591K | 202K | 283K | 46K |
| Total Current Liabilities | 2.64M | 4.82M | 7.99M | 19.89M | 12.67M |
| Long-term Debt | 0 | 29.15M | 24.48M | 9.61M | 2.73M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 1.71M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 29.21M | 24.48M | 13.25M | 4.44M |
| Total Liabilities | 2.64M | 34.02M | 32.47M | 33.14M | 17.11M |
| Common Stock | 5K | 5K | 5K | 5K | 11K |
| Retained Earnings | (8.33M) | (38.92M) | (72.89M) | (102.91M) | (132.58M) |
| Accumulated OCI | (0) | (73K) | (12K) | 5K | 1K |
| Other Stockholders Equity | (2) | 0 | 0 | 0 | 0 |
| Minority Interest | 74.16M | 37.15M | 12.58M | 1.5M | 8.5M |
| Total Equity | 121.57M | 74M | 25.44M | 3.49M | 41.51M |
| Total Debt | 0 | 30.21M | 30.1M | 29.71M | 4.32M |
| Net Debt | (117.45M) | 3.21M | 24.24M | 25.95M | (14.3M) |
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.